pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT
ADC Therapeutics
ADC Therapeutics SA
ADC Therapeutics is a pharma organization headquartered in Lausanne, CH. It trades on NYSE under ticker ADCT. Primary therapeutic focus areas include Non-Hodgkin Lymphoma, Advanced Solid Tumors, Relapsed or Refractory B-
Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lausanne, Vaud, Switzerland, CH
- Founded
- 2011
- Employees
- 272
- Programs
- 30
- Drugs
- 15
- Patents
- 22
ADCT-402-105
Phase 1 · other · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
ADCT-402-105 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma is a Phase 1 program (other) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Internal code ADCT-402-105
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ADC Therapeutics SA
- Phase
- Phase 1
- Modality
- other
- Indication
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- active
- Trials
- 1